Skip to main content

Stribild FDA Approval History

FDA Approved: Yes (First approved August 27, 2012)
Brand name: Stribild
Generic name: cobicistat, elvitegravir, emtricitabine and tenofovir
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection

Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

Development timeline for Stribild

Aug 27, 2012Approval FDA Approves New Combination Pill Stribild for HIV Treatment
May 11, 2012FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV
Dec 25, 2011U.S. FDA Accepts New Drug Application for Gilead's Once-Daily, Single-Tablet Quad HIV Regimen
Oct 28, 2011Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.